About UroMems
UroMems is a company based in Grenoble (France) founded in 2011. UroMems has raised $145.73 million across 7 funding rounds from investors including BNP Paribas, Crédit Agricole and Banque Populaire. UroMems offers products and services including UroActive. UroMems operates in a competitive market with competitors including Axonics, Amber Therapeutics, NeuSpera Medical, MyoPowers Medical Technologies and Levee Medical, among others.
- Headquarter Grenoble, France
- SectorsHealthcare
- Website uromems.com/en
- Social LinkedIn
- Total Equity Funding$145.73M (USD)
in 7 rounds
- Latest Funding Round$60M (USD), Series D
May 2026
- InvestorsBNP Paribas
& 15 more
Products & Services of UroMems
UroMems offers a comprehensive portfolio of products and services, including UroActive.
Smart implant for treating severe stress urinary incontinence.
Funding Insights of UroMems
UroMems has successfully raised a total of $145.73M across 7 strategic funding rounds. The most recent funding activity was a Series D round of $60 million completed in May 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $145.73M
- Total Rounds 7
- Last Round Series D — $60M
- First Round $2.15M
(Nov 2016)
- Investors Count 16
All 7 funding rounds of UroMems with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2026 | $60M | Series D | – | – | |
| Jun 2024 | $47M | Series C | – | Crédit Mutuel Innovation | |
| Apr 2021 | $8.31M | Series B | – | Financiere Arbevel, Supernova Invest | |
| May 2020 | – | Debt – Conventional | – | – | |
| May 2020 | $17.49M | Series B | – | Financiere Arbevel | |
| Nov 2016 | $2.15M | Grant | – | – | |
| Nov 2016 | $12.93M | Series A | – | Wellington Partners Venture Capital |
16 investors in total: 16 institutional.
Investors in UroMems
UroMems has secured backing from 16 investors, including venture fund and institutional investors. Prominent investors backing the company include BNP Paribas, Crédit Agricole and Banque Populaire.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Long-term investments in startups are facilitated by this company. | – | creditmutuel-innovation.eu | - | |
- | – | supernovainvest.com | - | |
Venture capital is provided to innovative startups by b2venture. | – | b2venture.vc | St. Gallen, Switzerland | |
Investments are made in early-stage healthcare startups. | – | wellington-partners.com | Munich, Germany | |
CITA is engaged in minority investments to support business growth. | – | cita-invest.com | Paris, France | |
Investments in startups are facilitated to valorize CEA technologies. | 1999 | cea-investissement.com | France | |
Institution of the European Union responsible for upholding the EU treaties | 1958 | ec.europa.eu | Brussels, Belgium | |
Corporate consultancy, advisory, and funding services are provided to businesses. | 2012 | bpifrance.com | Maisons Alfort, France | |
Investment management services are provided for clients in Paris. | 1997 | arbevel.com | Paris, France | |
- | – | hilinvent.tcc.mode | - |
Investor details for UroMems
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of UroMems
2 people are tracked at UroMems (2 in leadership).
| Name | Role | Group |
|---|---|---|
John Murphy | Chief Operating Officer | Leadership |
Hamid Lamraoui | CEO, Co-Founder & Board Director | Leadership |
Complete people profiles for UroMems
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of UroMems
3 dated milestones of UroMems across 15 years, from founding to its latest funding, stage changes and deals.
- Founded UroMems is founded.
- Funding First funding round of $2.2M.
- Funding Latest funding round, Series D, of $60.0M.
Competitors of UroMems
UroMems operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Axonics, Amber Therapeutics, NeuSpera Medical, MyoPowers Medical Technologies and Levee Medical, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| axonics.com | 2013 | Irvine, United States | $143.47M | 762 | Sacral neuromodulation devices are developed for urinary and bowel control. | |
| amber-tx.com | 2021 | London, United Kingdom | $100M | – | Bioelectrical therapies for peripheral nervous system disorders are developed. | |
| neuspera.com | 2014 | Santa Clara, United States | $123.59M | – | Miniaturized injectable neuromodulation devices are developed for chronic diseases. | |
| myopowers.eu | 2004 | Besancon, France | $32.99M | – | An implantable device for the treatment of urinary incontinence stress | |
| leveemedical.com | 2021 | Durham, United States | $24.15M | – | Urological devices for post-prostatectomy incontinence are developed by Levee Medical. | |
| americanmedicalsystems.com | 1972 | Minnetonka, United States | – | – | Devices for the treatment of pelvic disorders | |
| crimsonhealthcare.in | 2015 | Delhi, India | $439,262 | – | Medical devices for ostomy management are developed and supplied. | |
| attends.com | 1979 | Greenville, United States | – | 948 | Products for managing urinary and fecal incontinence in adults |
Detailed competitors of UroMems
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Uromems
Complete news archive for UroMems
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to UroMems
10 companies that operate in the same segment as UroMems (Genitourinary Disorders), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Therapeutics for drug-resistant bacterial infections are developed. | 2013 | Cambridge, Massachusetts, United States | USD 114.7 M | USD 59.62 M | 32 | |
Sacral neuromodulation devices are developed for urinary and bowel control. | 2013 | Irvine, California, United States | USD 143.47 M | – | – | |
Provider of surgical devices for vertical hernia repair and abdominal wall reconstruction | 2012 | Malvern, Pennsylvania, United States | USD 104.6 M | USD 80.28 M | 209 | |
Therapeutics for infectious and autoimmune diseases are developed. | 2010 | Cambridge, Massachusetts, United States | USD 470.49 M | – | 71 | |
Miniaturized injectable neuromodulation devices are developed for chronic diseases. | 2014 | Santa Clara, California, United States | USD 123.59 M | – | – | |
Developer of a therapeutic solution to treat prostate, kidney, and bladder cancer | 2018 | Maple Grove, Minnesota, United States | USD 157 M | – | 29 | |
A device is developed to treat urinary obstruction from BPH. | 2014 | Palo Alto, California, United States | USD 48 M | – | 25 | |
Minimally invasive devices in urology | 2004 | Mountain View, California, United States | USD 137.96 M | – | 119 | |
Diagnostic devices for lower urinary tract diseases are developed. | 2021 | Aliso Viejo, California, United States | USD 94.99 M | – | 23 | |
Medical device for benign prostatic hyperplasia treatment is developed. | 2021 | Milwaukee, Wisconsin, United States | USD 54.16 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about UroMems
UroMems was founded in 2011 and raised its 1st funding round 5 years after it was founded.
UroMems is headquartered in Grenoble, France. It is registered at Grenoble, Auvergne-rhone-alpes, France.
UroMems is a funded company, having raised a total of $145.73M across 7 funding rounds to date. The company's 1st funding round was a Grant of $2.15M, raised on Nov 2016.
Developer of active implantable devices for urological incontinence. The device MyoElectroMechanical System is based on a technology where a patients activity is measured in real-time through micro-sensors inside the implant into which algorithms are embedded; the system interprets data coming from the micro-sensors and computes the urethral pressure to apply.
UroMems's top competitors include Axonics, NeuSpera Medical and Amber Therapeutics.
UroMems offers UroActive.
UroMems has 16 investors. Key investors include BNP Paribas, Crédit Agricole, Banque Populaire, Caisse D Epargne, and European Commission.